Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A

Haemophilia

Volumn 23, Issue 5, 2017, Pages e427-e435

  Matsumoto, T ^a   Nogami, K ^a   Tabuchi, Y ^b   Yada, K ^a   Ogiwara, K ^a   Kurono, H ^b   Arai, N ^b   Shima, M ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

clot waveform analysis; factor VIII; haemophilia; inhibitor

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CLOT WAVEFORM ANALYSIS; COMPARATIVE STUDY; DISEASE SEVERITY; DOSE RESPONSE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; BLOOD; BLOOD CLOTTING TIME; DEVICES; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BLOOD COAGULATION TESTS; FACTOR VIII; HEMOPHILIA A; HUMANS; PARTIAL THROMBOPLASTIN TIME; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE BLOOD COAGULATION TIME;

EID: 85026316597     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13266     Document Type: Article

References (18)

1. White GC, Rosendaal F, Aledort LM, et al. Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society on thrombosis and haemostasis. Thromb Haemost. 2001;85:560.
2. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391-399.
3. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801-1809.
4. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost. 2008;34:128-141.
5. van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost. 2007;5(Suppl 1):151-156.
6. Nogami K, Shima M. Phenotypic heterogeneity of hemostasis in severe hemophilia. Semin Thromb Hemost. 2015;41:826-831.
7. Trossaert M, Boisseau P, Quemener A, et al. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost. 2011;9:524-530.
8. Shima M, Thachil J, Nair SC, Srivastava A. Towards standardization of clot waveform analysis and recommendations for its clinical applications. J Thromb Haemost. 2013;11:1417-1420.
9. Shima M, Matsumoto T, Fukuda K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost. 2002;87:436-441.
10. Matsumoto T, Shima M, Takeyama M, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006;4:377-384.
11. Haku J, Nogami K, Matsumoto T, et al. Optimal monitoring of bypass-therapy in hemophilia A patients with inhibitor using clot waveform analysis. J Thromb Haemost. 2014;12:355-362.
12. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia. 2008;14(Suppl 3):83-92.
13. Braun PJ, Givens TB, Stead AG, et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost. 1997;78:1079-1087.
14. Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015;94(Suppl 77):38-44.
15. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247-251.
16. Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014;40:803-811.
17. Knoebl K, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10:622-631.
18. Eubanks J, Baldwin WH, Markovitz R, et al. A subset of high titer anti-factor VIII A2 domain antibodies are responsive to treatment with factor VIII. Blood. 2016;127:2028-2034. pii: blood-2015-09-670034.